 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from scanned originals with text recognition applied 
(searchable text may contain so me errors and/or omissions) 
 
 
~ 1 
2 Date: (;.. \ I ~ I \ 1 L.D. 793 
(Filing No. S-32) ) 
3 Reproduced and distributed under the direction of the Secretary of the Senate. 
4 STATE OF MAINE 
s SENATE 
6 129TH LEGISLATURE 
7 FIRST REGULAR SESSION 
8 SENATE AMENDMENT "A-" to COMMITTEE AMENDMENT "A" to S.P. 237, 
9 L.D. 793, Bill, "An Act To Improve Accountability of Opioid Manufacturers" 
10 Amend the amendment in section 3 in ยง 13 724 by striking out all of subsection 2 
11 (page 2, lines 31 and 32 in amendment) and inserting the following: 
12 '2. Manufacturer of an opioid medication fee. The fee for a manufacturer of an 
13 opioid medication is $55,000. This subsection does not apply to a manufacturer of an 
14 opioid medication if all of that manufacturer's opioid medications are approved by the 
15 United States Food and Drug Administration for use only in veterinary medicine.' 
16 SUMMARY 
17 This amendment exempts from the opioid medication fee a manufacturer of opioid 
18 medications exclusively for use in veterinary medicine. 
19 FISCAL NOTE REQUIRED 
20 
21 
22 
23 (See attached) ----- SPONSOREDBY: ~ 
(President JACKSON) 
COUNTY: Aroostook 
Page 1 -129LR1130(03)-l ---------------------------------
SENATE AMENDMENT 
Approved: 06/18/19 wac::. 
129th MAINE LEGISLATURE 
LD793 LR 1130(03) 
An Act To Improve Accountability of Opioid Manufacturers 
Fiscal Note for Senate Amendment "ff' to Committee Amendment ''A" (S-32 ') 
Sponsor: Pres. Jackson of Aroostook 
Fiscal Note Required: Yes 
Fiscal Note 
Potential reduction in revenue received- Opiod Use Disorder Prevention and Treatment Fund 
Fiscal Detail and Notes 
Excluding manufacturers of an opioid product or products from the annual license fee for manufacturers of opioid 
medication under certain conditions may reduce the amount ofrevenue deposited into the Opioid Use Disorder 
Prevention and Treatment Fund from the annual license fee. The amount cannot be estimated at this time. 
LRl 130(03) -Fiscal Note -Page 1 of 1 
